• Anemia
• Intravenous iron • Iron deficiency
Ferric carboxymaitose (FCM, Ferinject') was effective and well tolerated in the treatment of iron-deficiency anemia (IDA) in nine, Phase III, randomized controlled, multlcenter trials in a diverse range of indications, including patients with inflammatory bowel disease (IBD), post-partum anemia (PPA) or abnormal uterine bleeding (AUB), chronic heart failure (CHF), non-dialysis-dependent chronic kidney disease (CICD) and those undergoing hemodialysis (HD).
In most trials, patients received either FCM doses of 1000 mg, administered intravenously (Lv.) over <15 mm. or oral ferrous sulfate (FeSuIf) 325mg (65 mg iron), three times daily (t.i.d.), or 304mg (100mg iron), twice daily (b.LdJ. in one trial, patients on HI) received 200mg Lv. of either FCM or iron sucrose (ISC), twoto-three times weekly. In a pilot study in patients with CHF and CKD, patients receIved 200 mg of FCM by push injection compared with 200mg of ISC slow Injection. FCM was usually administered until the patient's calculated total iron replacement dose was achieved.
Treatment with FCM Improved indices of anemia (hemoglobin [Hbl, ferritin and transferrin saturation ITSATI values). In patients on HD with IDA secondary to CKD, FCM demonstrated comparable efficacy to ISC in achieving an increase in Hb. In patients with IBD or PPA, Improvements in Hb levels were more rapid with FCM than with FeSuIf. Patients with PPA receiving FCM compared with those receiving oral iron achieved an Hb rise 2.0 g/dl earlier (7 days compared with 14 days; p <0.001), were more likely to achIeve an Hb rise 3.0 gldl at any time beginning at day 14 (86.3% compared with 60.4%; p< 0.001), and achieve an Hb >12.0 gldl at the end of the study (Day 42; 90.5% compared with 68.6%, p <0.01). Serum ferritln increased In the Lv. FCM treatment group, but not in the oral iron group. Differences between groups were significant at each study interval. TSAT increased significantly at every interval in both groups; however, FCM-treated patients showed higher TSAT at each interval after the first week. FCM improved patient quality of life to an equivalent extent to oral FeSuif in patients with IBD or PPA, and to a greater extent than oral FeSuif in women with AUB. FCM also improved quality of life as well as functional symptoms and exercise capacity in patients with CHF. Safety data from more than 3000 patients showed that FCM was well tolerated. No safety concerns have been identified in breastfed infants of mothers receiving FCM. FCM is, therefore, an effective and welltolerated option in the treatment of IDA.
Introduction
Iron(I1I)-hydroxide polymaltose complex (fenic carboxymaltose, FCM; Ferinject, Vifor (International) Inc., St. Gallen, Switzerland) is a novel, next-generation complex for intravenous (i. v.) iron treatment, developed to reduce the limitations of previous i. v. iron preparations such as high pH, high osmolarity, long administration time, or dosage limitations [11. FCM does not react with dextran antibodies, has a pH between 5.0 and 7.0, and up to 1000 mg iron (as FCM) can be infused within 15 mm 11] . FCM has a unique carboxymaltose shell, which leads to a highly stable, type I polynuclear iron The iron is taken up in a controlled way by the macrophages, and delivered to transfemn and ferritin via the physiological iron metabolism pathways.
To date, the safety and efficacy of FCM in correcting iron deficiency have been investigated in a diverse range of indications in ten completed Phase I -HI studies. The key findings of the following nine published Phase III studies will be discussed in this review:
adverse drug event adverse event abnormal uterine bleeding twice daily
Crohns disease chronic heart failure chronic kidney disease erythropoiesis-stimulating agent Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure ferric carboxymaltose ferrous sulphate gastrointestinal hemoglobin hemoclialysis hemodialysis-dependent chronic kidney disease intravenous inflammatory bowel disease iron-deficiency anemia iron sucrose intention-to-treat non-dialysis-dependent chronic kidney disease New York Heart Association per-protocol post-partum anemia quality of life 36-item short-form questionnaire three times daily treatment-emergent adverse event total iron-binding capacity transferrin saturation ulcerative colitis 2. FCM in the management of IDA secondary to IBD [2] Anemia is a frequent complication of IBD (Crohn's disease ICDI and ulcerative colitis IUCI) 12, 111. The cause of iron deficiency has been attributed to chronic blood loss from the ulcerated intestinal mucosa, and to impairment of iron intake and uptake, resulting in a negative iron balance 12, 121. In active disease, inflammatory mediators may alter iron metabolism (by retaining iron in the reticular-endothelial system), erythropoiesis, and erythrocyte survival. This condition is termed anemia of chronic disease. Iron supplementation should be initiated when IDA is present [131. In recent years, the use of oral iron replacement therapy for IBD has been questioned. Iron absorption may be compromised in patients with IBD, making oral iron therapy ineffective in patients with ongoing iron loss 121.
Intolerance and discontinuation due to adverse events (AE5) with oral iron are frequent 111]. In contrast, i.v. iron replacement, particularly with iron sucrose (ISC; Venofer®, Vifor (International) Inc.) has been found to be effective and well tolerated 1141, although a potential disadvantage is the need for repeated infusions and long infusion times; single doses should not exceed 500 mg iron per infusion per week', infused over at least 3.5 h. Secondary efficacy endpoints included: change in Hb, serum ferritin and TSAT from baseline to weeks 2, 4, 8, and 12; number and proportion of patients who achieved target levels of Hb, ferritin, and TSAT at weeks 2, 4, 8, and 12; proportion of patients discontinuing due to lack of response, QoL, and disease activity). AEs and concomitant medications were recorded at each visit.
Response (defined as the proportion of patients with an Hb increase of >2.0 g/dl) was faster for patients in the FCM group than those in the FeSulf group at week 2 (p = 0.005 1) and week 4 (p = 0.0346). The statistical analysis of the cumulative Hb responder rate over 12 weeks demonstrated a statistically significant difference between the treatment groups (log-rank test, p = 0.0009).
Median ferritin increased from 5.0 to 323.5 ig/l at week 2, and decreased to 43.5 ig/l at week 12). In the FeSuif group, a moderate increase from 6.5 to 28.5 tg/l at week 12 was observed. The final percentage of responders (defined as the proportion of patients with serum ferritin within target levels of 100-800 tg/l) at week 12 was 26.5% in the FCM group versus 3.3% in the FeSulf group (Kaplan-Meier analysis: log-rank test, p < 0.001).
TSAT increased in both groups, from 4% to 23% in patients treated with FCM, and from 6% to 17% in patients treated with FeSulf. The percentage of responders (defined as the proportion of patients with 20-50% TSAT) was significantly higher in the FCM group at week 2 (p = 0.0006) and week 4 (p = 0.0 130), but the point estimates at week 12 appeared similar. Analyses over the 12-week period, however, showed statistically significant differences between the two groups (log-rank test, p = 0.0086).
There was an improvement in Q0L in both groups, with a slightly higher median change from baseline in the SF-36 total score in the FCM group than in the FeSuIf group at all time points (+ 14 versus +8.6 at week 12) [21. Both the Crohn's Disease Activity Index and the Colitis Activity Index showed decreases in mean total scores during the study in both treatment groups, indicating that FCM may also improve Q0L.
FCM was well tolerated, and the dosing schedule was not associated with any clinically relevant safety concerns. Treatment-related AEs were experienced by 28 Three randomized, open-label, controlled studies have been conducted to compare the efficacy of largedose i. v. FCM (total iron dose was calculated using the Ganzoni formula, modified to include adjustment for baseline iron status) 1151 versus oral FeSuIf in women with IDA (defined as Hb 10.5 g!dl) within the 10-day had demonstrated previous non-adherence to prescribed oral iron therapy, active severe infection, serum TSAT >50%, serum ferritin >500 tg/l, received erythropoiesis-stimulating agents (ESAs) within 3 months of screening, a history of myelosuppressive therapy, or an hematological disorder other than iron deficiency. Premature withdrawal was required if an alternative intervention for the management of anemia was given. Red blood cell transfusion, initiation of ESAs or iron administration were not included in the study protocol.
One-hundred and seventy-four patients received 350 doses of i.v. FCM (mean total dose 1403 mg) in three, two, or one injections (19 [10.9 %l, 138 179.3 %J or 17 (9.8%] of patients, respectively); 178 patients received FeSulf. To estimate sample size, 80% of patients in each treatment group were assumed to be compliant with dosing and achieve the primary endpoint. Based on this assumption, a sample size of 160 patients per treatment group provided 85% power to achieve a 97.5% two-tailed lower confidence bound > 15% for the treatment difference (i. v. iron minus oral iron) in success rate. Health-related Q0L was assessed using normalized data from the SF-36 questionnaire 1191 and the Fatigue Linear Analog Scale Assessment 1201.
The primary efficacy endpoint was the proportion of patients with an Hb increase 2.0 g/dl post-treatment. There was no between-group difference in the proportion of patients who achieved a rise in Hb 2.0 g/dl at day 42 (96.4% versus 94.1%; p = 0.443). FCM was noninferior to oral FeSuIf (Fig. 1A) . Adherence to prescribed therapy was greater among patients in the i. v. FCM group compared with those in the oral FeSuIf group (mean adherence 98.0% versus 83.9 %).
Secondary efficacy endpoints included the proportion of patients attaining an Hb increase 3.0 g/dI and an Hb level 12.0 g/dl (correction of anemia; normal value used to assess response), time to achieve primary outcome, peak Hb increase from baseline, time to peak Hb increase, maximal increase in serum ferritin, TSAT, reticulocyte count, number of patients requiring intervention, time to intervention, proportion of patients with an Hb increase 2.0 g/dl and serum ferritin 16.0 ig/l, and the proportion of patients with improved Q0L. Patients receiving i. v. FCM were more likely to achieve an Hb rise 3.0 gIdl at any time from day 14 onwards during the study than those receiving FeSuIf (p <0.001; the proportion of responders at day 42 were 86.3 % versus 60.4%) (Fig. 1B) . Patients receiving i.v. FCM were more likely to achieve an Hb level 12.0 g/dl at the end of the study (day 42) (han those receiving FeSuIf (90.5% versus 68.6%, p <0.01) (Fig. IC) . Patients assigned to i.v. FCM achieved an Hb rise 2.0 g/dl sooner than those assigned to oral FeSulf (median time to achieve primary endpoint: 7 days compared with 14 days, respectively, p < 0.001).
Among patients assigned to i. v. FCM, overall erythropoeltic response (Hb, hematocrit. reticulocytes, mean corpuscular volume, mean corpuscular Hb and reticulocyte Hb content) was more robust at most treatment intervals than for patients treated with FeSuIf.
Serum ferritin increased rapidly in the i.v. FCM treatment group, but did not increase in the oral FeSuIf group (Fig. 1D) . Importantly, the serum femtin level was in the normal range at the end of the study in the FCM group. Differences between groups were significant at each study interval. TSAT increased significantly and at every interval in both groups, related to a rise in serum iron and a fall in total iron-binding capacity TSAT than patients treated with FeSuif at each interval after the first week, associated with a more pronounced rise in serum iron and fall in TIBC. No patient in either treatment group received red blood cell transfusion. Patient Q0L increased in both treatment groups; between-group differences were not significant. The within-group change from baseline to day 42 met or exceeded criteria for the minimum important difference for every health-related Q0L scale except SF-36 RoleEmotional.
Information on the efficacy of oral FeSuif in PPA in the current trial was restricted to 42 days of administration. Longer trials will be needed to confirm whether the higher iron stores achieved in patients treated with i. v.
iron signify a persistent treatment benefit in women with ongoing menses or subsequent pregnancy.
In the second non-inferiority study, conducted by Breymann et al. 131 , patients (aged 18-44 years) with PPA (Hb <10.5 gldl) were randomized (2: 1 ratio) to receive i. v. FCM over 2 weeks (up to three weekly doses of 1000 mg iron, maximum, per dose, given in 15 mm; maximum of three infusions; n = 227) or 304 mg FeSuif (100mg of iron), orally, b.i.d., for 12 weeks (n = 117). Changes in Hb and iron stores up to week 12 were analyzed (Table 1) . Patients with anemia other than that caused by blood loss secondary to delivery and iron deficiency were excluded from the study. The planned sample size of 348 patients was based on a 90 % power • to detect non-inferiority using a margin of 5.0 gIl and alpha of 0.025 (one-sided) and expected standard deviation of 12.0 gIl, with a 20% drop-out rate. The mean calculated iron deficit was 1365 mg (range 720-2024) and 1393 mg (range 829-1918) in the FCM and oral FeSulf groups, respectively (PP population). Primary efficacy endpoint was the change from baseline to week 12 in Hb levels. Intravenous FCM was as effective as FeSuIf in increasing Hb, despite the much shorter treatment period. Mean Hb changes from baseline to week 12 were 33.7 g/l and 32.9 g/l in the FCM and FeSulf treatment groups, respectively (Fig. 2) .
Secondary efficacy endpoints included change from baseline in fenitin and TSAT; response rate of patients achieving Hb levels of 12.0-16.0 g/dl; ferritin levels of 50-800 tg/l; TSAT levels of 20-50%; and the number and proportion of patients who needed transfusions.
Ferritin levels were significantly higher in patients treated with i.v. FCM than in patients treated with oral FeSuIf (p <0.0001). Mean ferritin levels increased from 39.9 ig/l at baseline to 568.2 tg/l at week 1 for patients in the FCM group. A decrease was seen in following weeks, but ferritin levels remained above baseline at all visits (mean: 161.2 ig/l at week 12). Patients in the FeSuIf group showed only a marginal ferritin increase from 32.4 ig/l at baseline to 43.3 tg/l at week 12 (p < 0.0001). Changes from baseline in mean TSAT values were significantly higher in the FCM group compared with the FeSuif group at all visits (p 0.0004). Response rates for TSAT were significantly higher in the FCM group at all visits; at week 2, 125 (69.8%) patients receiving FCM responded compared with 32 (36.0%) patients receiving FeSuif (p < 0.0001). Corresponding rates at 12 weeks were 139 (77.7%) for FCM and 59 (66.3%) for FeSulf (p <0.05). Only one patient (in the FCM group) had a transfusion to replace intra-operative blood loss.
Compliance with oral therapy was encouraged and monitored (unlike the "real-life" situation), and was very high (>90 %), but iron stores were nonetheless not replenished. Therefore, patients with more severe PPA might be at a higher risk of IDA once menstruation restarts. The iron deficit could also be carried forward to subsequent pregnancies.
A further superiority clinical trial, undertaken by Seid et al. 141, has also examined the efficacy, safety, and tolerability of i.v. FCM, compared with oral FeSuif in 291 women 10 days post-partum (mean i-lb on two or more laboratory tests) ( Table 1) . Women (aged 16-43 years) were randomized (1: 1) to receive FCM (n = 143) 1000 mg iron over 15 mm. repeated weekly to a calculated replacement dose (maximum 2500 mgi or FeSuIf (n = 148) 325 mg (65 mg iron), orally, t. i. d., for 6 weeks. The primary efficacy endpoint was the percentageof patients achieving Hb >12.0 g/dl between baseline and end of study. Exclusion criteria included: myelosuppressive therapy or asthma therapy and recent blood transfusions or erythropoietin therapy within the 3 months prior to screening. Study withdrawal was required if the patient needed an intervention (i. e., ESA, blood transfusion, or i. v. or oral iron outside the study protocol). Patients were also stratified according to average baseline Hb levels ( 8.Og/dl, 8.1-9.0 g/ dl, or 9.1-10.Og/dl), requirement for caesarean, and screening ferritin levels ( 25 or >25 ig/l).
It was assumed that success rates for the FeSuIf group and the FCM group were 70% and 80%, respectively, and the alpha level for the two-sided Fisher's exact test was 0.05. Accordingly, approximately 320 randomized patients would provide 300 patients for the modified ITF population (the protocol-specified primary population for evaluating all efficacy endpoints, treatment administration/compliance and subject characteristics) and 270 patients for the evaluable population to achieve Among patients who achieved an Hb level 12.0 g/dl at any time during the study, the largest difference between FCM and FeSulf groups was observed in patients whose baseline Hb was <8.0 g/dl (78.9% versus 43.5%; p = 0.0286) (Fig. 3) . The overall incidence of drug-related AEs, was lower in patients treated with FCM (15/ 142 I10.6%1) than with FeSuif (32/147 l21.8%1).
The findings of these three studies illustrate that highdose i. v. FCM is an effective treatment option for PPA, offering advantages over oral FeSuif in terms of rapid normalization of iron stores and reliable correction of anemia over a shorter treatment period.
392 Bailie -Femc carboxymaltose 4. FCM and IDA due to AUB [6] Women with AUB are often untreated or inadequately treated for anemia (21] . AUB impacts women's healthrelated Q0L and puts a heavy economic burden on society [221.
A multicenter, open-label, randomized, Phase III study was undertaken to determine the efficacy and safety of rapid, large-dose i. v. FCM versus oral FeSuIf in women with IDA secondary to AUB [61. Two-hundred and thirty women (aged 18 years or older) with IDA (defined as Hb 11.Og/dl, TSAT serum ferritin <100 ig/l) and AUB received FCM at a dose calculated to correct anemia and replenish iron stores ( 1000 mg iron over 15 mm, repeated weekly to achieve a total calculated replacement dose); 226 women received FeSulf, 325mg (65 mg elemental iron), t.i.d., for 6 weeks. Exclusion criteria included: red blood cell transfusion or parenteral iron administration within the prior 8 weeks, or an anticipated need for blood transfusion during the study; use of ESAs within the prior 12 weeks; initiation of hormonal therapy potentially affecting uterine bleeding in the 8 weeks before study entry; endometrial hyperplasia, and chronic viral infection. Randomization was stratified by Hb level ( 8.0, 8.1-9.5, or 9.6-11.0 g/ dl) and by degree of uterine bleeding during the previous 28 days (mild/moderate, severe, or very severe) and the presence or absence of a poor response to prior oral iron therapy. According to statistical power and sample size calculations and using a two-sided Fisher's exact test and 5% significance level, it was estimated that the study would have at least an 85% power to detect a 25% i. v. FCM treatment effect in comparison with oral FeSulf if at least 390 patients were enrolled (61.
Patients assigned to either group showed a similar severity of IDA at baseline (Hb, 9.4 g/dl in both groups; TSAT, 5.8% versus 5.6%; serum ferritin, 6.9 tg/l versus 6.8 g/l, in the i. v. FCM and FeSuIf groups, respectively). The primary efficacy endpoint was an increase in Hb 2.0 g/dl after initial treatment. Patients assigned to i. v. FCM were more likely to achieve an Hb rise 2.0 g/dl during the 42 days after baseline, than those receiving FeSuIf (82% versus 62%, respectively; p <0.001).
Other secondary efficacy endpoints included an increase in Hb 3.0 g/dI or an Hb level 12.0 g/dl, mean Hb increase, safety assessment, and Q0L scores. Patients assigned to i. v. FCM were more likely than those receiving FeSuIf to achieve an Hb rise 3.0 gIdl (53% versus 36%; p <0.001 from baseline) or correction of anemia ( to study drug, as determined by the investigators. No deaths occurred during the study. There was no difference between groups in the number of infections reported and no infection was thought to be related to study drug. Discontinuation of study drug due to AEs occurred in five patients in the FCM arm and seven patients in the FeSuif arm. Patients assigned to oral iron therapy were more likely to experience GI ADEs, particularly constipation (14.2% versus 3.0%) and nausea (11.9% versus 3.5 %). Those assigned to FCM were more likely to report headache (6.5% versus 4.4%) and transient fatigue (2.2% versus 0%). Transient, asymptomatic hypophosphatemia was also observed after FCM administration; this resolved spontaneously without specific treatment.
A potential limitation of this open-label trial is that patient-reported outcomes may have been affected by awareness of treatment assignment. This is particularly relevant of an i. v. versus an oral trial. However, healthrelated Q0L scores tend to increase with Hb level, regardless of treatment [231, and treatment-related improvement in fatigue, specifically that seen in open-label interventional trials, is also seen in trials in which patients are masked to treatment assignment 1241.
Patients who received FCM showed more rapid correction of iron depletion, iron-deficient erythropoiesis and anemia; greater improvement in health-related Q0L and fewer adverse GI symptoms than patients receiving oral FeSuIf. These responses were significantly different by day 14 for the primary outcome (Hb increase >2.0 g/dl) and by day 28 for the secondary outcome (Hb increase >3.0 g/dl), demonstrating the value of i. v. FCM in the early correction of iron deficiency in women post-partum, and in replacing ongoing blood losses in women with AUB.
FCM in patients with CHF [9]
In patients with CHF, anemia is an independent risk factor for hospital admission and mortality, and has been shown to worsen as the severity of the CHF progresses 125. 261. Beyond anemia, iron deficiency is becoming recognized as an important factor in CHF, which can mimic the symptoms of CHF and impact negatively on functional capacity and perceptions of health 127. 281. Conversely, it is possible that iron repletion in iron-deficient patients with CHF may improve symptoms as it has been shown to improve symptomatic and exercise performance in patients without heart failure 129, 301.
A recent study of iron repletion in patients with CHF (Ferinject® Inclusion criteria were glomerular filtration rate 45 ml! min/1.73 m2, Hb 11.0 g/dl, TSAT 25% and serum ferritin 300 igIl. ESA doses, if any, must have been stable for at least 8 weeks prior to administration of iron and remain so throughout the study. Major exclusion criteria included documented history of discontinuation of oral iron therapy due to GI distress and i. v. iron use during the 12 weeks prior to the study start. The primary efficacy endpoint was the percentage of patients achieving an increase in Hb 1.0 g/dl at any time point between baseline and the end of the study or the time of intervention.
Baseline characteristics, Hb, iron parameters, and mean iron deficit at baseline were similar in both groups. Mean compliance with the prescribed oral iron regimen was 95.8% (unlike the "real-life" situation). The primary efficacy endpoint, the proportion of patients achieving an Hb increase 1 g/dl, was significantly greater in the i. v. FCM group than in the FeSuif group Other efficacy endpoints included the percentage of patients achieving 1 g/dl increase in Hb by day 28; mean change to highest Hb; mean increase in Hb by day 42 and day 56; mean TSAT (%) and serum ferritin. FCM was also shown to be more efficacious than oral FeSuif across all ranked secondary endpoints. In patients receiving FCM, the percentage of patients achieving a 1 g/dl increase in Hb by day 28, the mean change to highest Hb (1.3 versus 0.8 gIdl, respectively; p <0.001), and the mean increase in Hb by day 42 (1.0 versus 0.5 g/dl, respectively; p <0.005) and 56 (1.0 versus 0.7 g/dl, respectively; p < 0.034) were all higher compared with patients receiving FeSulf. In patients with CKD not on dialysis, FCM (1000 mg iron over 15 mm, with one or two additional 500 mg iron doses) was more effective than oral FeSulf therapy.
A multicenter, open-label, randomized, parallel group Phase III study was conducted in 183 (PP population) adult patients (aged 18-80 years) undergoing HD or haemofiltration with IDA (defined as Hb <11.5 gIdl; TSAT <20%; or serum fen-itin <200 ig!l) secondary to CKD (81. Patients received either 200 mg iron as FCM (n = 97; ITT population) given without dilution as a bolus-push injection or as ISC (n = 86; IT'!' population) given over 10 mm. Both treatments were administered into the HD venous line, 1 h after the start of each dialysis session, two-to-three times weekly, until the total cumulative dose for each patient was reached. The maximum treatment period was 4 weeks and patients were followed for an additional 4 weeks. Patients were prescribed an ESA at baseline and must have received this treatment for at least 8 weeks prior to inclusion in the study. The ESA dose may have been decreased during the study, but no ESA dose increases were permitted during the study period. The primary response was defined as the percentage of patients reaching an Hb increase of at least 1.0 g/dl at 4 weeks post-baseline. The primary response was met by 46.4% (45/97) and 37.2% (32 /86) of patients in the FCM and ISC groups, respectively. Other efficacy endpoints included mean Hb levels during follow-up and serum ferritin levels. Mean Hb levels increased at the follow-up visit in both treatment groups: from 9.3 g/dl to 10.6 g/dl and from 9.3 g/dl to 10.3 g/dl in the FCM and ISC groups, respectively. Mean serum fenitin levels increased from baseline to week 2: from 90.4 ig/l to 723.4 ig/l and from 93.1 jig/I and 549.6 jig/I in patients treated with FCM and ISC, respectively (Fig. 4) (81. At the end of follow-up, mean serum ferritin values were 465.3 jig/i versus 397.7 jig/I for the FCM and ISC groups, respectively. As increased doses of ESA were not permitted during this randomized, controlled study, biases that may be introduced due to uncontrollable influences of Hb level are presumed to affect both groups equally, thus, the increase in Hb can be solely attributed to efficient iron utilization. There was a trend towards better response for Of those patients receiving FCM (n = 1968), 93% completed the study and approximately 88% (n = 1736) received a repletion dose of 1000 mg iron. The discontinuation rate due to any AE was similar in both groups (FCM group 1.5%; oral iron group 1.8%). No serious or life-threatening hypersensitivity (anaphylactoid) ADEs were reported with FCM. The most common ADE with FCM was headache (Table 3) 1381. Two non-serious hypersensitivity ADEs (0.1 %) were reported with no changes in vital signs. No symptomatic hypotension occurred. Mild-to-moderate transient skin changes (rashes, urticaria and itching) were observed. A decrease in serum phosphorus was observed; the decreases were transient and asymptomatic (Table 3 ). The overall ADE rate was lower for the FCM group (302/1968 patients; 15.3%) compared with the oral iron group (218/834 patients; (Table 5) .
A potential limitation of the pooled safety data for FCM and other i.v. iron treatments is that full assessment of the safety profiles of i. v. iron preparations is difficult to acquire. There may be significant inter-rater variability and possible subjectivity associated with the reporting of AEs by investigators across centers in a multicenter trial. Moreover, safety was assessed as a secondary endpoint in many of the trials. Clinical study designs are limited by exclusionary patient entry criteria, small numbers of exposed patients and short durations of treatment [411. There are many examples of important AEs that were not detected in clinical trials with other medications, but that were only discovered during post-marketing surveillance 1421. Moreover, more serious idiosyncratic adverse reactions are rare, which makes case ascertainment difficult, even in large patient populations. AEs excluded events relating to iron-deficiency anemia or the therapeutic effect of iron treatment (e.g., ferritin increase).
2) Event terms reported in four or more mothers or in three or more breast-fed infants in total, in descending order of frequency.
Reported as: elevated aspartate aminotransferase and/or alanine aminotransferase, biirubin or gamma-glutamyl transpeptidase. provement in all indices of anemia (rapid Hb increase and rapid normalization of iron stores, as assessed by serum ferritin and TSAT). In addition, in two studies [6, 7,1, i.v. FCM has been shown to be superior to oral FeSuIf in terms of the proportions of patients achieving "success" (in terms of Hb increase according to various definitions). In patients with IBD 121 or PPA 151, increases in Hb indicated a faster response to treatment with FCM than with oral FeSulf, while in patients with IDA secondary to CKD [8) , FCM demonstrated a comparable efficacy to ISC in achieving an increase in Hb 1.0 g/dl at 4 weeks post-baseline, although there was a trend of more pronounced increases on most response parameters in patients with FCM and with low baseline Hb values compared with the ISC arm. In all Phase III studies, FCM treatment led to a rapid and significant rise in mean serum fenitin, which remained elevated for several weeks alter the last infusion, indicating the utilization of stored iron during the weeks of hematopoiesis following the infusions.
Safety data from more than 3000 patients has shown that FCM is well tolerated with a low risk of immunogenicity. The incidence of AEs and the discontinuation rate due to AEs was lower in patients receiving FCNI than in patients receiving oral iron or i. v. ISC (in HD). No safety concerns have been identified in breast-fed infants of mothers receiving FCM.
Overall, FCM is considered to be an optimal treatment for parenteral iron administration, providing a very efficient and convenient means of delivering iron in patients with IDA.
